Could a lower dose of this thyroid cancer drug be just as good?
NCT ID NCT07092514
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two doses of the drug lenvatinib (24 mg vs 10 mg daily) in 34 people with advanced thyroid cancer that no longer responds to radioactive iodine. The goal is to see if the lower dose causes fewer side effects while still controlling the cancer. Participants take the drug by mouth and are monitored for tumor response and treatment tolerability.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenvatinib (Lenvima)
What this could lead to
If successful, this could show that a lower dose of lenvatinib is as effective but with fewer side effects, improving quality of life for patients with advanced thyroid cancer.
What could go wrong
This is a small, early-phase trial with only 34 participants, so results may not apply broadly. The lower dose might be less effective at controlling the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact